McNeice Paul Francis sold $1K of AMWL

McNeice Paul Francis (Chief Accounting Officer) sold 112 shares of American Well Corp (AMWL) at $11.80 on 2026-09-01.

Original reporting
SEC EDGAR · McNeice Paul Francis
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMWL
Neutral
high confidence
Mentioned
$AMWL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMWLNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock.

02

Market read

Minor insider sell with limited trading relevance.

03

What to watch

Potential upcoming earnings or corporate actions not disclosed in this filing.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions; traders watch for material changes in insider holdings.

Company-level read

Ticker impact

$AMWLNeutralHigh confidence
Context

Chief Accounting Officer sold 112 shares for $1,321.60 on 2026-09-01, reducing his stake to 9,739 shares.

Expected impact

No material price movement expected.

Evidence & confidence

The sale amount is small relative to the insider's holdings and overall market cap.

Market effects

No broader sector impact; the transaction is company‑specific.

Limited to US market participants tracking AMWL.

None

Counterpoint

Even small insider sells can signal concerns; monitor for further disposals.

Key entities

  • McNeice Paul Francis

    Chief Accounting Officer of American Well Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.